CCM
KRON

CAAS Capital Management’s Kronos Bio KRON Stock Holding History

CAAS Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$448K – 1282
2020
Q4 		$448K Buy
+15,000
New +$471K ﹤0.01% 705

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's KRON Position: Q1 2021 in Review

CAAS Capital Management sold out of Kronos Bio (KRON) in Q1 2021, closing a stake of 15,000 shares — an estimated $448K sold.

CAAS Capital Management first reported a position in KRON in Q4 2020 and held it in 1 quarter. The position peaked at $448K in Q4 2020. 71 funds tracked by Wall St. Rank hold KRON as of Q1 2021.

  • CAAS Capital Management reported no remaining Kronos Bio position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 15,000 Kronos Bio shares in Q1 2021, an estimated $448K.
  • CAAS Capital Management first reported a position in Kronos Bio in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Kronos Bio position peaked at $448K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.